Cargando…
EGF-IL2 bispecific and bivalent EGF fusion toxin efficacy against syngeneic head and neck cancer mouse models
The epidermal growth factor receptor (EGFR) remains one of the best molecules for developing targeted therapy for multiple human malignancies, including head and neck squamous cell carcinoma (HNSCC). Small molecule inhibitors or antibodies targeting EGFR have been extensively developed in recent dec...
Autores principales: | Qiu, Yue, Qi, Zeng, Wang, Zhaohui, Cao, Yu, Lu, Ling, Zhang, Huiping, Mathes, David, Pomfret, Elizabeth A., Lu, Shi-Long, Wang, Zhirui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827275/ https://www.ncbi.nlm.nih.gov/pubmed/36579667 http://dx.doi.org/10.3892/or.2022.8474 |
Ejemplares similares
-
A novel diphtheria toxin‐based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma
por: Qi, Zeng, et al.
Publicado: (2021) -
Bispecific human IL2‐CCR4 immunotoxin targets human cutaneous T‐cell lymphoma
por: Wang, Haoyu, et al.
Publicado: (2020) -
CCR4‐IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T‐cell lymphoma in a mouse CTCL model
por: Wang, Zhaohui, et al.
Publicado: (2023) -
Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck
por: Reuter, C W M, et al.
Publicado: (2007) -
Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck.
por: Ishitoya, J., et al.
Publicado: (1989)